Pulse cyclophosphamide for corticosteroid-refractory
graft-versus-host disease.

J 2005

Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease.

MAYER, Jiří; Marta KREJČÍ; M. DOUBEK; Z. POSPÍŠIL; Yvona BRYCHTOVÁ et al.

Základní údaje

Originální název

Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease.

Název česky

Puls cyklofosfamidu na kortikoid-rezistentní GVHD.

Autoři

MAYER, Jiří; Marta KREJČÍ; M. DOUBEK; Z. POSPÍŠIL; Yvona BRYCHTOVÁ; Miroslav TOMIŠKA a Zdeněk RÁČIL

Vydání

Bone Marrow Transplantation, London, Nature publishing group, 2005, 0268-3369

Další údaje

Typ výsledku

Článek v odborném periodiku

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.643

Označené pro přenos do RIV

Organizační jednotka

Lékařská fakulta

UT WoS

000227827100009

Klíčová slova česky

akutní GVHD, cyklofosfamid, imunosuprese

Klíčová slova anglicky

acute GVHD; cyclophosphamide; immunosuppression

Změněno: 3. 11. 2010 15:13, prof. MUDr. Zdeněk Ráčil, Ph.D.

Anotace

V originále

Corticosteroid-resistant GVHD is difficult to manage and is associated with high morbidity and mortality. Cyclophosphamide (Cy) is an established immunosuppressive and cytotoxic drug widely used as part of pretransplant conditioning regimens. In a retrospective study of 15 patients who had not responded to corticosteroids (nine with acute GVHD, three with GVHD after donor leukocyte infusion, and three progressive chronic GVHD), pulse Cy at a median dose of 1 g/m(2) was very effective in the treatment of skin (100% response), liver (70% response), and the oral cavity (100% response). Severe intestinal GVHD responded poorly. The toxicity pro. le was acceptable, with manageable, short-term myelosuppression in some patients. The risk of opportunistic infections, mixed chimerism, relapses, or post-transplant lymphoproliferative disease was not increased. Overall survival was 57%, with median and maximum follow-up of 9 and 37 months, respectively. The cost of the drug was negligible, especially when compared to monoclonal antibodies. Pulse Cy requires further investigation in corticosteroid-resistant GVHD.

Citovat

MAYER, Jiří; Marta KREJČÍ; M. DOUBEK; Z. POSPÍŠIL; Yvona BRYCHTOVÁ; Miroslav TOMIŠKA a Zdeněk RÁČIL. Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease. Bone Marrow Transplantation. London: Nature publishing group, 2005, roč. 35, č. 1, s. 699-705. ISSN 0268-3369.

@article{573451,
   author = {Mayer, Jiří and Krejčí, Marta and Doubek, M. and Pospíšil, Z. and Brychtová, Yvona and Tomiška, Miroslav and Ráčil, Zdeněk},
   article_location = {London},
   article_number = {1},
   keywords = {acute GVHD; cyclophosphamide; immunosuppression},
   issn = {0268-3369},
   journal = {Bone Marrow Transplantation},
   title = {Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease.},
   volume = {35},
   year = {2005}
}

TY  - JOUR
ID  - 573451
AU  - Mayer, Jiří - Krejčí, Marta - Doubek, M. - Pospíšil, Z. - Brychtová, Yvona - Tomiška, Miroslav - Ráčil, Zdeněk
PY  - 2005
TI  - Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease.
JF  - Bone Marrow Transplantation
VL  - 35
IS  - 1
SP  - 699-705
EP  - 699-705
PB  - Nature publishing group
SN  - 02683369
KW  - acute GVHD
KW  - cyclophosphamide
KW  - immunosuppression
N2  - Corticosteroid-resistant GVHD is difficult to manage and is associated with high morbidity and mortality. Cyclophosphamide (Cy) is an established immunosuppressive and cytotoxic drug widely used as part of pretransplant conditioning regimens. In a retrospective study of 15 patients who had not responded to corticosteroids (nine with acute GVHD, three with GVHD after donor leukocyte infusion, and three progressive chronic GVHD), pulse Cy at a median dose of 1 g/m(2) was very effective in the treatment of skin (100% response), liver (70% response), and the oral cavity (100% response). Severe intestinal GVHD responded poorly. The toxicity pro. le was acceptable, with manageable, short-term myelosuppression in some patients. The risk of opportunistic infections, mixed chimerism, relapses, or post-transplant lymphoproliferative disease was not increased. Overall survival was 57%, with median and maximum follow-up of 9 and 37 months, respectively. The cost of the drug was negligible, especially when compared to monoclonal antibodies. Pulse Cy requires further investigation in corticosteroid-resistant GVHD.
ER  -

MAYER, Jiří; Marta KREJČÍ; M. DOUBEK; Z. POSPÍŠIL; Yvona BRYCHTOVÁ; Miroslav TOMIŠKA a Zdeněk RÁČIL. Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease. \textit{Bone Marrow Transplantation}. London: Nature publishing group, 2005, roč.~35, č.~1, s.~699-705. ISSN~0268-3369.

Přehled o publikaci